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AbstrACt
Introduction Social capital, characterised by trust, 
reciprocity and cooperation, is positively associated with 
a number of health outcomes. We test the hypothesis that 
among hypertensive individuals, those with greater social 
capital are more likely to have their hypertension detected, 
treated and controlled.
Methods Cross-sectional data from 21 countries in the 
Prospective Urban and Rural Epidemiology study were 
collected covering 61 229 hypertensive individuals aged 
35–70 years, their households and the 656 communities 
in which they live. Outcomes include whether 
hypertensive participants have their condition detected, 
treated and/or controlled. Multivariate statistical models 
adjusting for community fixed effects were used to 
assess the associations of three social capital measures: 
(1) membership of any social organisation, (2) trust in 
other people and (3) trust in organisations, stratified into 
high-income and low-income country samples.
results In low-income countries, membership of any 
social organisation was associated with a 3% greater 
likelihood of having one’s hypertension detected and 
controlled, while greater trust in organisations significantly 
increased the likelihood of detection by 4%. These 
associations were not observed among participants in 
high-income countries.
Conclusion Although the observed associations are 
modest, some aspects of social capital are associated 
with better management of hypertension in low-income 
countries where health systems are often weak. Given 
that hypertension affects millions in these countries, even 
modest gains at all points along the treatment pathway 
could improve management for many, and translate into 
the prevention of thousands of cardiovascular events each 
year.
IntroduCtIon
Hypertension is a leading avoidable cause of 
cardiovascular disease-related deaths world-
wide.1 Evidence that hypertension control is 
inadequate in many settings calls for better 
understanding of how to improve detec-
tion, treatment and control, especially in 
resource-deprived settings.
One factor that could promote better 
patient management of hypertension is 
social capital. The World Bank defines social 
capital as the 'internal social and cultural 
coherence of society, arising from the norms 
and values that govern interactions among 
people and the institutions in which they are 
embedded'.2 It has long been recognised as a 
contributor to economic growth and overall 
human well-being, with several studies 
confirming its beneficial association with 
health outcomes, including self-reported 
health, depression and all-cause mortality.3–7 
Social capital acts at the individual and 
community levels and is often characterised 
by three dimensions8: (1) bonding, referring 
to the connections within networks of family 
members and helps individuals access care 
and resources; (2) bridging, which expands 
social networks through friends of friends 
and may help individuals get ahead in life 
and (3) linking, which involves connections 
across social classes and may help individuals 
access resources that they otherwise would 
not be able to.4 6
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In theory, the ability of social capital to help people 
obtain information and services could help hyperten-
sive patients overcome barriers to attaining care. As 
few experience symptoms, they must be able to access 
services where their condition can be detected and regu-
larly monitored.9 Both lifestyle changes and medicine 
adherence can be facilitated by support from friends and 
family, including potentially the means of accessing and 
affording medicines.10 There are many ways in which 
the information and support networks that characterise 
social capital could help hypertensive patients to over-
come the many barriers they face,11 ranging from lack of 
knowledge of the consequences of hypertension and its 
treatment, lack of motivation, social pressures, stress and 
anxiety and the effects of poor memory.
In this analysis, we test the hypothesis that greater indi-
vidual social capital improves rates of detection, use of 
treatment and overall control of hypertension. We focus 
on the bridging and linking types of social capital that 
extend beyond the home and family, as there is already a 
body of research on bonding capital, regarding how fami-
lies provide care and support for loved ones with chronic 
disease and this is less amenable to intervention.5 11 We 
further hypothesise that bridging and linking aspects 
of social capital will be more important in areas where 
health systems are weak.
MetHods
data
The Prospective Urban and Rural Epidemiology 
(PURE) study is a large global study of cardiovascular 
disease incidence, mortality and risk factors.12 Data are 
collected from urban and rural communities within 21 
countries including 4 high-income countries (HICs) 
(Canada, Sweden, Saudi Arabia, United Arab Emirates); 
7 upper-middle-income countries (UMICs) (Argentina, 
Brazil, Chile, Poland, Malaysia, South Africa, Turkey); 
5 lower-middle-income countries (LMICs) (China, 
Colombia, Iran, Occupied Palestinian Territory, Philip-
pines) and 5 low-income countries (LICs) (Bangladesh, 
India, Pakistan, Tanzania, Zimbabwe). The selection of 
countries in PURE was designed to achieve a balance 
between different economic levels, heterogeneity in 
social and economic circumstances and policies and 
the capacity of centres to collect high-quality data with a 
modest budget.12
PURE’s data collection is described in detail else-
where12–14; briefly, each country selected communities 
to include rural and urban populations, while ensuring 
feasibility of intended data collection methods (eg, 
processing blood samples) and long-term follow-up. 
Communities were defined as groups of people who 
reside within a specific geographic area and who were 
generally expected to have similar characteristics (eg, 
culture, socioeconomic status, use of amenities, goods 
and services). Existing administrative boundaries, such 
as village limits or postal code areas, or physical features 
(eg, area bounded by selected streets) were used to 
define urban communities, while rural communities 
were defined as villages or postal code areas located at 
least 50 km away from an urban centre. Households were 
selected to be broadly representative of their communi-
ties. All individuals within each selected household aged 
35–70 years were eligible, and 1 50 447 individuals were 
enrolled. Each participant was interviewed using a stan-
dardised questionnaire, which collected data on lifestyle 
and behaviour, cardiovascular disease risk factors, health 
history, use of medications and social capital. Sitting blood 
pressure was measured twice by trained research assis-
tants following a standardised procedure using a digital 
blood pressure measuring device (Omron HEM-757) 
and the average of these two measures was recorded. 
Community-level data, including availability and costs of 
medicines, and availability of public and private health-
care providers, were collected using the Environmental 
Profile of a Community’s Health instrument.15 Ethics 
Key questions
What is already known about this topic?
 ► Only two previous studies have examined social capital’s effect 
on the management of hypertension, both of which combined 
multiple measures of social capital to derive an overall index of an 
individual’s social capital for use in their analyses.
 ► A Finnish study of hypertensive employees found no association 
between social capital and adherence to antihypertensive 
medication; and another cross-sectional study of hypertensive 
adults in India, Pakistan and Bangladesh produced no evidence 
for an association between social capital and any of the three key 
stages of hypertension management: the likelihood of diagnosis, 
use of antihypertensive medication or control.
What are the new findings?
 ► Our study examines the same three outcomes as the second study 
reported above; but contrary to previous studies, we show that 
social capital is associated with the management of hypertension.
 ► Consistent with leading theoretical conceptualisations of 
social capital that identify distinct forms with different causal 
mechanisms, only some forms of social capital were found to 
modestly increase the likelihood of having one’s hypertension 
detected and controlled, but not treated with medications.
 ► Crucially, these associations were only present among participants 
from low-income countries where health systems may be less 
well-equipped to provide care for chronic conditions.
recommendations for policy
 ► Given that cardiovascular disease is now the leading cause of 
death worldwide, with hypertension as the key modifiable risk 
factor, our findings provide insight to policy makers and planners 
on how to leverage social capital to benefit public health.
 ► This is important as improving population-level hypertension 
control requires a multifaceted approach.
 ► This evidence is of particular relevance for low-income countries 
where health budgets are constrained, because interventions 
based on social capital could be envisaged that would promote 
inclusiveness and cross-sectoral participation at relatively low 
cost.
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committees at each centre approved the protocol, which 
has been published elsewhere,12–14 and all participants 
provided written informed consent.
In this analysis, only participants with hypertension 
were included, defined as those having an average 
systolic blood pressure (SBP) of at least 140 mm Hg, or 
an average diastolic blood pressure (DBP) of at least 
90 mm Hg, or self-reporting as diagnosed with hyperten-
sion. We evaluated three binary outcomes of hyperten-
sion management: (1) detection, (2) treatment and (3) 
control among those with hypertension using the above 
definition. To isolate the stage in the pathway from detec-
tion to control where social capital has an effect, we also 
examined two conditional outcomes: (4) hypertension 
treatment and (5) control among those with detected 
hypertension. Detection was defined as having received a 
previous diagnosis of hypertension and to be using anti-
hypertensive medication; treatment as using antihyper-
tensive medication. Control was defined as participants 
with a history of hypertension whose average SBP and 
DBP was <140/90 mm Hg.
Following previous research, we measured bridging 
social capital in terms of participation in member-
ship organisations and trust in people.16 Thus, our first 
bridging social capital variable, individual participation 
in local organisations, is denoted by membership, which 
takes the value one if individuals self-report as being 
members of any one of the following: self-help group, 
co-operative, social club, sports club or religious group; 
while it takes the value zero otherwise. It has been shown 
that social relationships between individuals sharing the 
same social identity increase well-being and informal 
insurance arrangements.8 Our second bridging variable, 
trust in people, is coded as one if individuals state they 
strongly believe that people are generally honest and 
want to help others, or if they strongly believe that others 
will reciprocate the respect shown to them, and zero 
otherwise. Informal mechanisms of insurance heavily rely 
on mutual trust.17
To capture linking social capital, we measure trust in 
organisations, based on how much individuals trust that 
organisations can be relied on for help in difficult situa-
tions. Again, we code this as one if individuals state that 
they can rely a great deal on civic or religious organisa-
tions for help, and zero otherwise.
Models included individual controls (sex, age, marital 
status, dummies for highest level of education obtained, 
household wealth quintile, urban-rural location, current 
or recent history of tobacco use, alcohol user, diabetes, 
depression, obesity, pregnancy, recent loss of employ-
ment), community controls (availability of any public 
health facility, any private health facility, availability of 
any antihypertensive medications at a retail pharmacy, 
number of different antihypertensive medication catego-
ries available at a retail pharmacy and potential proxies 
for community social capital18: presence of electric street 
lighting, presence of any traffic lights and completeness 
of paved roads) and country and year dummy variables 
that capture national and annual effects not otherwise 
directly measured. Online supplementary appendix file 
1 provides full definitions of all model variables.
statistical modelling
To avoid issues with collinearity, we assessed the relation-
ship between each social capital variable (eg, member-
ship) and our hypertension management outcomes (eg, 
detection) using separate ordinary least-square models 
adjusting for community fixed effects (ie, communi-
ty-specific slopes) as follows:
 
detectionic − detectionc = β1(membershipic − membershipc)
+ β2(Iic − Ic) + β3(Cc − C)
+ β4(γic − γc) + β5η + (εic − εc) 
where the subscript i stands for the individual, and the 
subscript c for the community; I is a vector of explana-
tory variables at individual and household level, C is a 
vector of explanatory variables at community level, γ is a 
year dummy, η is a country dummy, ε is the disturbance 
term. Terms with a bar (eg, detectionc) are the average 
observations over i individuals within community c.
We stratified the analysis into HICs and UMICs (ie, 
high-income countries), where we assumed that health 
systems will be stronger, and LMICs and LICs (ie, 
low-income countries), where we assumed that they 
will be weaker (see online supplementary appendix file 
2). The stratification was based on World Bank income 
groups. We rejected stratifying based on existing 
measures of health system performance as they include 
health outcomes, thereby risking circularity. For each 
social capital variable, we tested for the equality of 
regression coefficients across country groups using the 
Chow test.19
results
Characteristics of the 61 229 hypertensive participants 
identified in the PURE sample are shown in table 1. 
About half (52%) of the participants identified in HICs 
and UMICs had their condition detected, compared 
with 43% in LMICs and LICs. Those who were being 
treated with antihypertensive medications ranged from 
35% in LMICs and LICs up to 48% in UMICs and HICs. 
Hypertension control was poor in countries at all levels 
of economic development, averaging 11% in LMICs and 
LICs up to 17% in HICs and UMICs.
Turning to social capital (figure 1), the proportion of 
hypertensive individuals who were members of a civic or 
religious organisation (bridging social capital) ranged 
from 29% in the LMIC and LIC group up to 37% in the 
HIC and UMIC group. However, few hypertensive indi-
viduals in each country grouping expressed a great deal 
of trust in such organisations (linking social capital), 
ranging from about 2% in LIC and LMICs up to 17% 
in HICs and UMICs; while many more reported a high 
degree of trust in other people (bridging social capital, 
from 35% in HICs and UMICs up to 51% in LMICs and 
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LICs). Detailed summary statistics for all social capital, 
individual, household and community-level variables by 
country income group are shown in online supplemen-
tary appendix file 3.
Associations of social capital with hypertension detection, 
treatment and control
Table 2 presents the estimated crude associations 
between the three social capital variables and each 
unconditional outcome along the hypertension 
management pathway from detection, through treat-
ment with medication, to control in all hypertensive 
participants while controlling for age, sex and hetero-
geneity across countries (because of the very different 
levels of hypertension outcomes) using country dummy 
variables. This shows that membership in a social organ-
isation is significantly associated with better detection, 
treatment and control in low-income countries (ie, 
LMICs and LICs), but only with detection and treat-
ment in high-income countries (ie, HICs and UMICs). 
There is no significant association with the other two 
social capital variables.
Table 3 then presents similar analysis, but controlling 
for a wide range of other variables, as noted above using 
the most conservative community fixed effect specifi-
cation. In this fully adjusted model, it is only in low-in-
come countries that membership in a social organisation 
Table 2 Crude associations between social capital variables and hypertension detection, treatment and control (among all 
hypertensive participants) by country income group, ordinary least-square estimates from model specification including only 
age, sex and country dummies as controls
Dimension of social 
capital
Hypertension detection Hypertension treatment Hypertension control
HIC and UMIC LMIC and LIC HIC and UMIC LMIC and LIC HIC and UMIC LMIC and LIC
Membership
  Coefficient 0.020* 0.090** 0.016* 0.083** 0.002 0.050*
  SE 0.008 0.012 0.008 0.013 0.005 0.010
  Number of individuals 25 178 15 860 25 178 15 860 25 178 15 860
  R2 0.087 0.085 0.103 0.105 0.045 0.025
  P value for difference in 
coefficients†
0.0000 0.0000 0.0000
Trust in people
  Coefficient −0.004 0.001 −0.004 −0.011 0.002 −0.004
  SE 0.008 0.010 0.008 0.009 0.006 0.005
  Number of individuals 25 177 30 061 25 177 30 061 25 177 30 061
  R2 0.087 0.061 0.102 0.080 0.045 0.027
  P value for difference in 
coefficients† 
0.7393 0.5181 0.3812
Trust in organisations
  Coefficient 0.014 0.024 −0.004 0.010 0.003 0.000
  SE 0.011 0.022 0.010 0.023 0.008 0.017
  Number of individuals 24 937 29 858 24 937 29 858 24 937 29 858
  R2 0.088 0.059 0.103 0.079 0.045 0.027
  P value for difference in 
coefficients† 
0.7711 0.6499 0.8325
*P<0.05, **P<0.01, when testing hypothesis that coefficient is equal to 0.
†P value from Chow test for the equality of coefficients between HIC and UMIC vs LMIC and LIC groups.
HIC, high-income countries; LIC, low-income countries; LMIC, lower-middle-income countries; UMIC, upper-middle-income countries.
Figure 1 Levels of self-reported individual social capital by 
country income group.
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is positively associated with the probability that hyper-
tension will be detected, treated and controlled. The 
increased probabilities are modest, at 2.9% (95% CI 0.3% 
to 5.6%), 2.8% (95% CI 0.3% to 5.3%) and 2.7% (95% 
CI 0.9% to 4.6%), respectively. There was no significant 
association with membership in high-income countries for 
any of the three outcomes. There was significant hetero-
geneity in the association with membership across country 
income groups for hypertension control (P=0.0203). No 
notable associations or differences across country groups 
were observed between the other bridging social capital 
variable, trust in people, or the linking variable, trust in 
organisations, and any of the hypertension management 
outcomes (detection, treatment or control), regardless 
of country income grouping. Results from other less 
conservative models are shown in online supplementary 
appendix file 4.
Identifying the mechanisms by which social capital may 
influence hypertension management
If social capital improves adherence and access to 
treatment, over and above enhancing detection, then 
the small positive associations would persist after 
controlling for a detection effect. If, however, the only 
means of improvement were via increased detection, 
then there would be no residual effect on treatment 
and control after adjusting for detection. Table 4 shows 
the estimated conditional associations from the most 
conservative community fixed effect specification 
between the three social capital variables and hyperten-
sion treatment and control, using only those who have 
already had detected hypertension.
In this group, the association between membership and 
treatment seen in the larger sample of hypertensive 
participants was no longer present (table 4). However, 
Table 3 Fully adjusted associations between social capital variables and hypertension detection, treatment and control 
(among all hypertensive participants) by country income group, ordinary least-square estimates from model specification 
including individual controls †, community controls ‡ and community fixed effects
Dimension of social 
capital
Hypertension detection Hypertension treatment Hypertension control
HIC and UMIC LMIC and LIC HIC and UMIC LMIC and LIC HIC and UMIC LMIC and LIC
Membership
  Coefficient 0.012 0.029* 0.008 0.028* 0.002 0.027**
  SE 0.008 0.013 0.007 0.013 0.005 0.010
  Number of individuals 22 381 10 467 22 381 10 467 22 381 10 467
  R2 0.104 0.087 0.123 0.093 0.026 0.019
  P value for difference in 
coefficients § 
0.2631 0.1754 0.0203
Trust in people
  Coefficient 0.004 −0.002 0.004 0.000 0.003 0.001
  SE 0.008 0.009 0.007 0.008 0.006 0.004
  Number of individuals 22 372 23 784 22 372 23 784 22 372 23 784
  R2 0.103 0.058 0.123 0.062 0.026 0.012
  P value for difference in 
coefficients §
0.6441 0.6927 0.7561
Trust in organisations
  Coefficient 0.011 0.039 −0.002 0.000 0.008 0.011
  SE 0.010 0.023 0.010 0.024 0.007 0.018
  Number of individuals 22 222 23 756 22 222 23 756 22 222 23 756
  R2 0.104 0.058 0.124 0.062 0.026 0.012
  P value for difference in 
coefficients§
0.2696 0.9419 0.8686
* P<0.05, **P<0.01, when testing hypothesis that coefficient is equal to 0.
 †Individual and household controls include sex, age, marital status, dummies for highest level of education obtained, dummies for 
household wealth quintiles, urban-rural location, current or recent history of tobacco use, alcohol user, diabetes, depression, obesity, 
pregnancy, recent loss of employment, dummies for country and year of data collection.
‡Community controls include availability of any public health facility, any private health facility, availability of any antihypertensive 
medications at a retail pharmacy, number of different antihypertensive medication categories available at a retail pharmacy, presence of 
electric street lighting, presence of any traffic lights and completeness of paved roads.
 §P value from Chow test for the equality of coefficients between HIC and UMIC vs LMIC and LIC groups.
HIC, high-income countries; LIC, low-income countries; LMIC, lower-middle-income countries; UMIC, upper-middle-income countries.
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among those whose hypertension had been detected, 
membership increased the likelihood of control by an 
average of 3.2%, although the 95% CI just included zero 
(0.0%–6.5%) and only in low-income countries. Hetero-
geneity tests confirmed that this association with member-
ship was present among those only in the low-income 
countries.
Finally, we limited the analysis to low-income countries 
and stratified it by urban and rural setting (table 5). The 
association between membership and hypertension control 
remained in both settings although, while the size of the 
coefficient was similar to that in the overall sample, in 
rural settings it was of borderline statistical significance 
(P=0.064). In this case, trust in organisations was signifi-
cantly associated with improved detection, but only in 
rural areas where it is to be expected that health systems 
may be weaker.
robustness checks and model validity
We assessed the robustness of our findings using a series 
of model specifications, including only individual-level 
controls as well as individual-level plus community-level 
controls in both the full sample of all hypertensive partic-
ipants (online supplementary appendix file 4) and the 
subsample of those with their hypertension detected 
(online supplementary appendix file 5). None of the 
results were qualitatively changed. However, the estimated 
associations from the specifications including only indi-
vidual controls, and individual plus community controls 
tended to be of a greater magnitude, consistent with 
potential unobserved community confounding factors.
The estimated associations of our covariates were 
in the anticipated direction, adding to the validity of 
our findings. The full model results, including those 
for the full range of control variables, are provided in 
online supplementary appendix file 6. Briefly, the statis-
tically significant positive associations of non-modifiable 
control variables, such as sex, age and comorbidities (eg, 
depression and diabetes) on hypertension management 
outcomes were consistent both across country income 
grouping and model specification.
Table 4 Associations between social capital variables and hypertension detection, treatment and control (among participants 
aware of their hypertension) by country income group, ordinary least-square estimates from model specification including 
individual controls *, community controls† and community fixed effects
Dimension of social capital
Hypertension treatment Hypertension control
HIC and UMIC LMIC and LIC HIC and UMIC LMIC and LIC
Membership
  Coefficient −0.002 0.014 −0.001 0.032
  SE 0.007 0.012 0.009 0.016
  Observations 11 683 4912 11 683 4912
  R2 0.040 0.042 0.019 0.015
  P value for difference in coefficients‡ 0.2425 0.0728
Trust in people
  Coefficient 0.005 −0.007 0.007 0.004
  SE 0.007 0.009 0.010 0.008
  Observations 11 679 10 516 11 679 10 516
  R2 0.040 0.019 0.019 0.009
  P value for difference in coefficients‡ 0.2820 0.7960
Trust in organisations
  Coefficient −0.014 −0.037 0.008 −0.002
  SE 0.009 0.029 0.012 0.029
  Observations 11 614 10 494 11 614 10 494
  R2 0.041 0.020 0.019 0.009
  P value for difference in coefficients‡ 0.4533 0.7474
 *Individual and household controls include sex, age, marital status, dummies for highest level of education obtained, dummies for household 
wealth quintiles, urban-rural location, current or recent history of tobacco use, alcohol user, diabetes, depression, obesity, pregnancy, recent 
loss of employment, dummies for country and year of data collection.
†Community controls include availability of any public health facility, any private health facility, availability of any antihypertensive 
medications at a retail pharmacy, number of different antihypertensive medication categories available at a retail pharmacy, presence of 
electric street lighting, presence of any traffic lights and completeness of paved roads.
‡P value from Chow test for the equality of coefficients between HIC and UMIC vs LMIC and LIC groups.
HIC, high-income countries; LIC, low-income countries; LMIC, lower-middle-income countries; UMIC, upper-middle-income countries.
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dIsCussIon
Although the association between social capital and 
health status has been examined extensively elsewhere, 
this is the first cross-regional study that examines its 
association with the management of common non-com-
municable diseases (NCDs) or their risk factors. In addi-
tion, very few studies on social capital and health have 
included low-income and middle-income countries, 
which now account for the majority of the NCD burden.
Our findings differ between countries at different 
income levels, which we take as a proxy for health system 
strength: we find no detectable association of bridging 
or linking social capital with hypertension management 
in high-income countries. This is unsurprising as they 
have effective institutions and procedures that leave little 
scope for social networks to bring additional benefit 
in obtaining care. This finding is consistent with other 
research showing that the health benefits associated with 
social capital are less in countries with better functioning 
employment protection systems.20 However within 
high-income countries, social capital may still have an 
important function for groups with poorer access to care. 
While such analysis is beyond the remit of this paper, the 
question does warrant further research.
In low-income countries, which we consider to be 
more likely to have weaker systems, we find that individ-
ual-level social capital is associated with an increase in 
the likelihood of having hypertension detected, treated 
and controlled, although modestly, linked to bridging 
social capital, as measured by participation in civic and 
religious organisations. The observed positive associ-
ation with treatment is explained entirely by increased 
detection, as indicated by the conditional analysis among 
known hypertensives. Linking social capital is also asso-
ciated with increased detection, although only in rural 
areas of low-income countries, where we would expect 
health systems to be especially weak. Importantly, the 
coefficients are consistently in the expected direction. 
These associations are small, as expected. The quality of 
hypertension management is largely a reflection of the 
wider health system, including affordability and avail-
ability of medicines, as shown in other analyses using 
Table 5 Associations between social capital variables and hypertension detection, treatment and control (among all 
hypertensive participants) in LMICs and LICs only by urban-rural location, ordinary least-square estimates from model 
specification including individual controls†, community controls‡ and community fixed effects
Dimension of social capital
Hypertension detection Hypertension treatment Hypertension control
Urban Rural Urban Rural Urban Rural
Membership
  Coefficient 0.024 0.033 0.028 0.024 0.025* 0.030
  SE (0.018) (0.020) (0.017) (0.020) (0.012) (0.016)
  Observations 6163 4304 6163 4304 6163 4304
  R2 0.083 0.100 0.091 0.096 0.019 0.023
  P value for difference in coefficients§ 0.7368      0.8946 0.7694
Trust in people
  Coefficient 0.000 −0.005 0.007 −0.011 0.006 −0.007
  SE (0.011) (0.013) (0.011) (0.011) (0.006) (0.005)
  Observations 13 330 10 454 13 330 10 454 13 330 10 454
  R2 0.054 0.067 0.059 0.069 0.012 0.014
  P value for difference in coefficients§ 0.7560      0.2363 0.0936
Trust in organisations
  Coefficient 0.019 0.057* 0.007 −0.007 0.016 0.003
  SE (0.034) (0.029) (0.039) (0.028) (0.032) (0.016)
  Observations 13 311 10 445 13 311 10 445 13 311 10 445
  R2 0.054 0.067 0.059 0.069 0.012 0.014
  P value for difference in coefficients § 0.3873 0.7619 0.7097
*P<0.05,  when testing hypothesis that coefficient is equal to 0.
†Individual and household controls include sex, age, marital status, dummies for highest level of education obtained, dummies for household 
wealth quintiles, urban-rural location, current or recent history of tobacco use, alcohol user, diabetes, depression, obesity, pregnancy, recent 
loss of employment, dummies for country and year of data collection.
‡Community controls include availability of any public health facility, any private health facility, availability of any antihypertensive 
medications at a retail pharmacy, number of different antihypertensive medication categories available at a retail pharmacy, presence of 
electric street lighting, presence of any traffic lights and completeness of paved roads.
§P value from Chow test for the equality of coefficients between HIC and UMIC vs LMIC and LIC groups.
HIC, high-income countries; LIC, low-income countries; LMIC, lower-middle-income countries; UMIC, upper-middle-income countries.
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PURE data,21 as well as of personal characteristics such as 
education and income.22 All of these are controlled for in 
our models, so any observed association is in addition to 
these factors. Our model also adjusts for behaviours such 
as smoking as they may reveal unobserved factors such as 
time preferences.23
Our use of community fixed effects models removes 
many unobserved factors at that level, including commu-
nity-level social capital, which we were unable to measure 
directly. This could bring further benefits, although 
other studies have found its impact to be limited.3 17 
Consequently, our estimates must be considered some-
what conservative.
Before interpreting our findings, we note several limita-
tions. First, while we have directly adjusted for potential 
confounding factors, there may be residual endogeneity, 
as with any observational study. A lack of available data 
and the cross-sectional design limit our ability to establish 
causality. Second, our binary measures of individual-level 
social capital are blunt measures of a complex concept 
and do not take into account the intensity of social partic-
ipation, for example. The PURE study was not designed 
to measure social capital as a primary aim, although the 
tool employed questions adapted from previous social 
capital studies, and collected information covering all 
social capital dimensions. We also cannot rule out the 
potential effect of healthy volunteer selection bias; and 
all social capital variables were not collected in every 
country (see online supplementary appendix file 3). 
Finally, our study did not include a measure of bonding 
social capital, which may have even more substantial and 
positive impacts on hypertension management. Data on 
whether family members could be counted on in diffi-
cult situations was collected to inform this dimension of 
social capital only in a subset of countries (Saudi Arabia, 
Turkey, Philippines, Bangladesh, Zimbabwe, Tanzania). 
Supplemental analysis showed that bonding social capital 
did not modify the association of the bridging and linking 
forms with hypertension management, which were the 
main foci of this study.
Several possible mechanisms may be involved. Social 
capital may facilitate exchange of information on the 
quality of services and informal mechanisms of obtaining 
care, thereby increasing detection. Trust in civic and 
religious organisations may spill over to trust in the 
health system, thus increasing the likelihood of seeking 
healthcare, leading to detection, and regular moni-
toring once diagnosed.24 These outcomes could also 
arise from the support and influence of the trust invested 
in people and trustworthy interpersonal networks that 
result from increased social participation. For example, 
organisational membership could bring individuals into 
contact with others with similar common conditions, 
thereby enhancing knowledge of hypertension and 
how to manage it, making it easier to access care, and 
providing informal support that motivates individuals 
to seek regular care, adhere to medication and main-
tain long-term lifestyle changes. Evidence from other 
studies provides some support for such mechanisms. For 
example, a Swedish study found some evidence for an 
association between low social participation and poor 
adherence to antihypertensive treatment25, while a study 
of British patients with chronic heart disease or diabetes 
found that social networks provided a substitute for 
formal care, improving self-management outcomes and 
reducing healthcare costs.26 Better adherence to lifestyle 
modifications was also observed in a longitudinal study of 
British smokers, where trust and social participation were 
positively associated with smoking cessation.27 Clearly, 
further research, particularly qualitative investigation, is 
needed to understand better the complex mechanisms 
at work.
Our findings suggest that, in low-income countries, 
social capital increases the probability of treatment by 
enabling more people with hypertension to be diag-
nosed. In other words, if we consider the entire hyperten-
sion management pathway, being a member and having 
trust in social organisations may encourage people to 
seek care, which in turn may increase the probability that 
they will be diagnosed. This is unsurprising; the decision 
to seek care is made by the individual, although subject 
to a variety of facilitators and constraints. It is the health 
professional who, after treatment has been sought, is 
primarily responsible for the decision to recommend 
treatment and he or she will largely be uninfluenced by 
the individual’s social capital. However, the individual 
with hypertension must also accept treatment, a decision 
likely to be influenced by the availability and affordability 
of medicines.21 Thus, the absence of an effect may be 
because the type of support provided by social networks 
is not primarily financial. Because antihypertensive medi-
cations are unaffordable for many in low-income and 
middle-income country settings and typically require large 
out-of-pocket payments,21 such networks provide little 
help in this regard, at least in relation to long-term finan-
cial commitments. Social capital does, however, seem to 
play a modest role in improving control. Although a 3% 
improvement in hypertension detection, treatment and 
control may seem unimportant, given that hypertension 
affects millions in low-income countries, with less than 
half being detected, about one-fourth being treated and 
only about one-sixth controlled, such an improvement at 
all of the points along the treatment pathway represents 
improved management of several tens of millions of 
people, which should translate into the prevention of a 
several tens of thousands of cardiovascular events each 
year. In addition, the benefits of social capital may extend 
to other conditions that require detection and long-term 
treatment such as diabetes, so the cumulative impact of 
enhanced social capital across multiple conditions could 
be substantial.
Our results have potential implications for policy. They 
reinforce the call by Woolcock and Narayan to consider 
social capital as a component of health systems reform 
in low-income countries,28 reiterating the importance 
of embedding change in existing social structures and 
group.bmj.com on January 20, 2018 - Published by http://gh.bmj.com/Downloaded from 
10 Palafox B, et al. BMJ Glob Health 2017;2:e000443. doi:10.1136/bmjgh-2017-000443
BMJ Global Health
strengthening trust in institutions. There are several 
opportunities to do this, drawing on evidence from 
research on community-driven development that social 
capital can be strengthened.29 First, reforms should 
incorporate participatory processes, and especially those 
that transcend social and other divides. Our findings and 
those from the studies cited above highlight the poten-
tial role that social networks play, bridging such divides, 
to benefit the management of long-term conditions like 
hypertension. They also point towards the potential for 
community and network-centred approaches to support 
health literacy and chronic illness management, which 
some have suggested may be more appropriate for 
engaging people in socially and economically deprived 
contexts.5 Second, reforms should include measures 
that enhance trust in public health facilities, including 
measures to strengthen the quality and acceptability of 
care, and information disclosure and other efforts to 
promote transparency. Third, they should explore oppor-
tunities for strengthening the exchange of information 
on services and how to access them. Of course, all these 
are justified in themselves, but these findings point to a 
non-trivial health benefit.
In conclusion, greater bridging and linking social 
capital may help individuals with hypertension to access 
and benefit from healthcare where health systems are 
weak. It is not an alternative to strengthening health 
systems, but it may play an important role in improving 
management. Health system reform should recognise 
this, where possible, adopting measures that increase 
social capital (evaluating its effects, given the scarcity of 
research), but at a minimum avoid policies that erode it 
by damaging trust and fragmenting networks.
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